Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy

Hypertension Research

Volumn 25, Issue 6, 2002, Pages 865-873

  Suzuki, Hiromichi ^a   Kanno, Yoshihiko ^a   Ikeda, Naofumi ^a   Nakamoto, Hidetomo ^a   Okada, Hirokazu ^a   Sugahara, Souichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Ejection fraction; Left ventricular hypertrophy

Indexed keywords

ANTIDIABETIC AGENT; BENAZEPRIL; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INSULIN; PLACEBO;

ADULT; AGE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DETERIORATION; DIABETIC NEPHROPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENDER; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; REVIEW;

EID: 0036867222     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.865     Document Type: Review

References (44)

1. Valderrabano F, Berthoux F, Jones E, Mehis O: Report on management of renal failure in Europe. XXV. 1994. End stage renal disease and dialysis report. Nephrol Dial Transplant 1996; 11 (Suppl 1): 2-21.
2. US Department of Health and Human Services: United States Renal Data System: 1998 Annual Data Report. Bethesda, MD, US Department of Health and Human Services, 1999.
3. Japanese Society for Dialysis Therapy: An Overview of Regular Dialysis Treatment in Japan. Tokyo, Japanese Society for Dialysis Therapy, 1999.
4. Ritz E, Rychlik I, Locateili F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-809.
5. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
6. Gall MA, Rosssing P, Skott P, et al: Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655-661.
7. Olivarius N de F, Andrreasen A, Keiding N, Mogensen C: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: cross-sectional data from the population-based study: "Diabetes Care in General Practice" Denmark. Diabetologia 1993; 36: 1007-1016.
8. Ravid M, Brosh D, Ravid Safran D, Levy Z, Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Ann Intern Med 1998; 11: 998-1004.
9. Messerli F, Goldbourt U: High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447-2452.
10. Mogensen C: Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. Am J Cardiol 1998; 82: 4R-8R.
11. UK Prospective Diabetes Study: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
12. Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-38.
13. Zhou A, Yu L, Li J, Zhang J, Wang H: Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor. Hypertens Res 2000; 23: 391-397.
14. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-2446.
15. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
16. Ritz E, Orth S: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
17. Alderman C: Adverse effects of the angiotensin-converting enzyme inhibitor. Ann Pharmacother 1996; 20: 193-200.
18. Opsahl J, Abraham P, Keane W: Angiotensin-converting enzyme inhibitors in chronic renal failure. Drugs 1990; 39 (Suppl 2): 23-32.
19. Awazu M, Ichikawa I: Alterations in renal function in experimental congestive heart failure. Semin Nephrol 1994; 14: 401-411.
20. Sasaguri M, Noda K, Tashiro E, et al: The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. Hypertens Res 2000; 23: 317-322.
21. World Health Organization: Diabetes Mellitus; Report of a WHO Study Group (Tech. Rep. Ser. No 727). World Health Org, 1985.
22. Devereux R, Reichek N: Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 1325-1350.
23. Hypertension in Diabetes Study Group: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors or cardiovascular disease. J Hypertens 1993; 11: 309-317.
24. Arauz-Pacheco C, Raskin P: Hypertension in diabetes mellitus. Endocrinol Metab Clin North Am 1996; 118: 401-423.
25. Levy D, Salomon M, D'Agostino R, Belanger A, Kannel W: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
26. Grossman E, Messerli F: Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304-310.
27. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
28. Kasiske B, Kalil R, Ma J, Liao M, Keane W: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
29. Ruggenenti P, Perna A, Benini R, Giusepp R: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9: 2096-2101.
30. Shigehara T, Sato A, Hayashi K, Saruta T: Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res 2000; 23: 219-226.
31. Bakris G, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.
32. Suzuki H, Saruta T: Benidipine. Cardiovasc Drug Rev 1996; 7: 58-63.
33. Suzuki H, Saruta T, and the Calcium Antagonist in Progressive Renal Insufficiency Study Group: Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens 2001; 23: 189-201.
34. Hansson L, Zanchetti A, Carruthers S, et al: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
35. Pahor M, Tatti P: Fosinopril versus amlodipine cardiovascular events trial (FACET) and combination therapies. Am J Cardiol 1999; 83: 819-829.
36. Weidmann P, Schneider M, Bohlem L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10(Suppl 9): 39-45.
37. Gansevoort R, De Zeeuw D, De Jong P: Is the anti-proteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
38. Brenner BM, Cooper ME, De Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
39. Parving H-H: Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60: 2041-2055.
40. Heeg J, de Jung P, van der Hem G, de Zeeuw D: Reduction of proteinuria and blood pressure by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78-83.
41. Yoshioka T, Shiraga H, Yoshida Y, et al: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease: study in the rat model of subtotal nephrectomy. J Clin Invest 1988; 82: 1614-1623.
42. Sioufi A, Pommier F, Godbillon J: Pharmacokinetics of benazepril and benazeprilat in hypertensive patients with renal impairment: biliary excretion in humans. Eur J Drug Metab Pharmacokinet 1993; 99-104 (Special Issue).
43. Hirakata H, Onoyama K, Hori K, Fujishima M: Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 1986; 26: 27-32.
44. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.